Recent 8-K filings for EVMN
Highest-materiality recent filing
Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise
- Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.
- Positive Phase 2a POC data for EVO301 in atopic dermatitis: met primary endpoint, 33% placebo-adjusted EASI reduction at week 12 after 2 doses.
-
Evommune Q2 net loss $32.2M; EVO756 AD Phase 2b data due Sept 2026
Net loss of $32.2M for Q2 2026 vs $13.6M in Q2 2025; cash $288M as of June 30, 2026.
-
Evommune EVO756 Phase 2b misses primary endpoint in CSU; development halted for that indication
Phase 2b trial of EVO756 in 160 CSU patients did not meet primary endpoint of UAS7 change at 12 weeks at any dose.
-
Evommune reports Q1 net loss $21.7M; EVO756 Phase 2b data due June 2026 in CSU
Net loss $21.7M in Q1 2026 vs $14.6M prior year; cash, equivalents and investments $307.0M as of March 31, 2026.
-
Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise
Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.
-
Evommune announces $125M private placement of 4.5M shares at $27.88/share
Gross proceeds ~$125M from sale of 4,494,279 shares at $27.88 per share to institutional investors.
-
Evommune reports positive Phase 2a top-line data for EVO301 in atopic dermatitis
Primary endpoint met: 99.8% of posterior distribution exceeded 8% improvement threshold vs placebo.
-
Evommune reports Q3 2025 net loss $12.5M; IPO raised $172.5M, three Phase 2 readouts due in 2026
Completed IPO in Nov 2025 of 10.78M shares at $16.00, raising $172.5M gross proceeds.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event other_material